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Abstract: Amphiphilic molecules have been actively explored as promising materials in the field of 
bio and nanotechnology. These molecules are constituted by a polar head and a lipophilic tail and 
in an aqueous medium are self-assemble to form different types of macromolecular structures such 
as micelles, monolayer vesicles, bars, sheets and tubes. In this work, a convergent synthetic 
approach for the synthesis of two new amphiphilic compounds based on a versatile amino polar 
head, a tetraethylene glycol spacer and a lipophilic tail derived from oleic acid has been developed. 
Subsequently, after a self-assembly process in aqueous medium, nanostructures as micelles have 
been obtained and characterized. Finally, a procedure for the inclusion of the highly lipophilic drug 
Dexamethasone has been carried out in order to study the ability of these micelles to act as 
nanovectors for drug delivery.  
Keywords: amphiphilic compounds; self-assembly; nanovectors; drug delivery 
 
1. Introduction 
In the last years, amphiphilic molecules have been highly used in the development of 
nanostructures, representing a great promise for targeted delivery, improved bioavailability, and 
drugs controlled release 1–7]. These molecules consist of a polar head and a lipophilic tail that are 
distributed in an aqueous medium to form different types of structures such as micelles, monolayer 
vesicles (also known as liposomes), bars, sheets and tubes 8]. The cell membrane of living cells, 
formed by a bilayer self-organization is the most illustrative example of a complex nanosystem 
formed from units of phospholipid. Among the different types of structures formed by amphiphilic 
compounds, micelles have received growing scientific attention 9]. Micelles, in general, are self-
assembled particles composed of amphiphilic compounds 10]. In an aqueous environment, these 
compounds are distributed with the hydrophobic tails in the centre of the micelle, and the polar heads 
towards the aqueous medium. In this way, they auto-assemble to form spheroidal structures with a 
hydrophilic shell and a hydrophobic core to minimize the contact of the hydrophobic segments with 
the aqueous environment by allowing a good grade of stability 11]. CMC, critical micelle 
concentration, is a relatively small range of concentrations separating the limit below which virtually 
no micelles are detected and the limit above which virtually all additional amphiphilic molecules 
form micelles.  
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Micelles have a particle size between 10 and 100 nm that is important to allow a high stability 
and a high bioavailability. This size makes it possible to inject these micelles into systemic circulation 
without risk of blood vessel blockage. The fate in vivo of micelles depends on their sizes, particles 
under 200 nm are less phagocytosed by macrophages after the opsonization, compared to those with 
larger dimensions 12].  
One of the advantages of using micelles in drug delivery is their ability to transport drugs with 
different degrees of polarity thanks to their structure consisting in a hydrophilic shell and a 
hydrophobic core. 
Drugs will be distributed differently by chemical conjugation, physical entrapment or ionic 
interactions depending on the nature of the drug and the amphiphilic compound properties: 
Hydrophilic drugs will bind to the surface (case 1), those with different hydrophilicity and 
lipophilicity ratios will be between the polar part and the lipophilic part of the nanosystem (case 2), 
and finally very lipophilic drugs will be distributed inside the micelle core (case 3) (Figure 1) 9]. 
 
Figure 1. Possible pattern of drug association with a micelle 9]. 
It is known that about 90% of drugs are lipophilic and are characterized by a low solubility in 
water, this causing a difficult distribution and accumulation in fatty tissues leading to a delayed 
release of the drug and an increase of side effects. Micelles are therefore used for the transport of 
highly lipophilic drugs, increasing the solubility of drugs from 10 to 8400 times and consequently 
their bioavailability 13,14].  
One of the most successful examples of micellar formulation as alternative solubilizing agents is 
the formulation of paclitaxel (PTX) in a poly (D, L-lactide) MePEG diblock copolymer which increases 
the solubilized PTX levels in water around 5000 times 15]. 
Micelles can also be used in active targeting, directing the drug towards the specific cell-tissue-
organ. Ligands such as carbohydrates 16], folic acid 17], antibodies 18], proteins 19], peptides 20] 
and aptamers 21,22] have been used.  
In summary, the main advantages of micelles in drug delivery are the following:  
i) high dynamic stability that permits their application in vivo 
ii) the hydrophobic core of micelles confers them the ability to transport highly lipophilic drugs 
iii) the hydrophilic shell of micelles increases their solubility in water, resulting in greater 
bioavailability and lower toxicity for poorly water-soluble drugs. 
iv) the possibility of modifying their surface with specific ligands confers the ability to direct drugs 
to specific targets.  
This work is placed in the field of nanotechnologies applied to drug delivery and specifically 
focused on the synthesis of amphiphilic compounds in order to obtain a new family of micelles as 
drug nanovectors within the organism.  
Both of these amphiphilic compounds synthesized present a versatile amino polar head, a spacer 
and a lipophilic tail. The spacer in all cases is tetraethylene glycol, a polymer derived from 
polyethylene glycol which presents two important advantages: (i) an adequate hydrophilic-
hydrophobic balance for the optimal formation of the micelle and (ii) the ability to avoid the 
activation of the immune system. It has been discovered that PEG derivatives are biocompatible and 
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they are not attacked by macrophages escaping the opsonization. Furthermore, the amphiphilic 
compounds synthesized present oleic acid as the lipophilic tail (Scheme 1). 
 
Scheme 1. General structure of the amphiphilic compounds. 
Micelles have been obtained in water by a self-assembly process of the amphiphilic compounds 
synthesized. After the characterization of micelles, the internalization of Dexamethasone, a synthetic 
highly lipophilic anti-inflammatory corticosteroid drug 23], has been studied in order to verify the 
advantages of the use of our micelles in drug delivery (Scheme 2). 
 
Scheme 2. Formation of micelles by supramolecular self-assembly of amphiphilic compounds and 
internalization of Dexamethasone. 
2. Method 
2.1. Materials and Techniques 
Unless otherwise stated, the starting materials, reagents, and solvents were purchased as high-
grade commercial products from Sigma-Aldrich. THF, CH2Cl2, DMF and Toluene were dried using 
molecular sieves, and highest quality solvents were used. All non-aqueous reactions were performed 
under an argon atmosphere in oven-dried glassware.  
Analytical TLC was run on silica gel plates supported by alluminio Alufram® Sil.G / V245 
Merck di 0.25 nm. Plates eluted and dried with 5% of phosphomolybdic acid in ethanol.  
Flash chromatography was performed on glass column using silica gel type 60 (particle size 
230–400 mesh, Merck). The composition of the eluent used is different for each compound, as 
indicated. 
1H- and 13C- spectra were recorded on a Bruker AMX-500 e Bruker Advance DRX-500 (500 
MHz) instrument at rt at the centre of Research, Technology and Innovation of the University of 
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Seville’s NMR core facility. Chemical shifts (δ) are expressed in parts per million relative to the 
residual solvent peak for 1H and 13C nucleus (acetone-d6: δH = 2.05, δC = 29.84; CDCl3: δH = 7.26, 
δC = 77.16; DMSO-d6: δH = 2.50, δC = 39.52; methanol-d4: δH = 3.31, δC = 49.00); coupling constants 
(J) are in hertz (Hz). The following abbreviations are used to describe peak patterns when 
appropriate: s (singlet), d (doublet), t (triplet), q (quartet), sext (sextuplet), m (multiplet), app 
(apparent), and br (broad). 
High resolution mass spectrometry (HRMS) was carried out on a Kratos MS-80-RFA 
spectrometer and in a AutoSpec micro-mass spectrometer at the centre of Research, Technology and 
Innovation of the University of Seville. 
2.2. Synthesis of the Amphiphilic Derivatives 
Synthesis of the First Amphiphilic Derivative 
1,11-mesyl-3,6,9-trioxaundecane (1) 
To a solution of tetraethylene glycol (8.90 mL, 15.49 mmol) in dry THF (200 mL) under argon 
atmosphere, and Et3N (17.9 mL, 128.71 mmol) was added MsCl (9.96 mL, 128.71 mmol) drop by drop 
at 0°C and was stirred for 1 h. After this time the mixture was allowed to warm slowly at room 
temperature. Then the solvent was evaporated and the mixture was dissolved in CH2Cl2 (50 mL) and 
washed 3 times with NH4Cl (3 × 15 mL), afterwards was neutralized with NaHCO3 (15 mL) and 
washed with brine (15 mL). The organic extract was dried over anhydrous Na2SO4, filtered, and 
evaporated to obtain the product 1 as a yellowish oil (5.42 g, 15.48 mmol, 99.97%). 
Rf (CH2Cl2/MeOH 9:1): 0.62 
1H NMR (500 MHz, CDCl3): δ 4.383–4.365 (m, 4H, CH2CH2OMs), 3.776–3.677 (m, 4H, CH2CH2OMs), 
3.671–3.633 (m, 8H, OCH2CH2O), 3.066 (s, 6H, CH3). 
13C NMR (125.7 MHz, CDCl3): δ 70.752, 70.620 (CH2O), 69.331, 69.128 (CH2CH2OSO2), 52.689 
(CH2OSO2), 37.769 (OSO2CH3). 
HRMS calcd for C10H22O9S2 [M + H] +: 351.0778; found 351.0778. 
1,11-diazido-3,6,9-trioxaundecane (2) 
To a solution of 1 (18.80 g, 53.66 mmol) in dry EtOH (35.8 mL) was added sodium azide (8.72 g, 
134.15 mmol). The mixture was allowed to reflux during 24 h, under argon atmosphere and after this 
time, was added NaCl (50 mL) to deactivate the sodium azide. Then the solvent (EtOH) was removed 
by rotary evaporation. Successively the mixture was extracted with CH2Cl2 in order to obtain the 
product in the organic phase, and after all, was evaporated the solvent. Then the crude product was 
purified by flash chromatography column on silica gel with AcOEt: Hexane (1:2), to yield 2 as a 
yellowish oil (11.9 g, 48.71 mmol, 91%). 
Rf (AcOEt/Hexane 3:1): 0.58 
1H NMR (500 MHz, CDCl3): δ 3.694–3.654 (m, 12H, OCH2CH2O and CH2CH2N3), 3.386 (t, J = 5 Hz, 
4H, CH2N3). 
13C NMR (125.7 MHz, CDCl3): δ 70.856 (CH2O), 70.162 (CH2CH2N3), 50.846 (CH2N3). 
HRMS calcd for C8H16N6O3Na [M + Na] +: 267.1176; found 267.1179 
11-azido-3,6,9-trioxaundecan-1-amine (3) 
To a solution of 2 (7.83 g, 32.04 mmol) in HCl 1M (96.10 mL) and ethyl acetate (56.91 mL) at 0 °C, 
was added dropwise a solution of triphenylphosphine (9.24 g, 35.24 mmol) in ethyl acetate (85.36 
mL). Afterwards, the temperature was allowed to reach room temperature and stirred over 7 h. The 
mixture was separated in a separatory funnel, and in the aqueous phase was added NaOH until PH 
>14 (5 mL). Successively was added CH2Cl2 (30 mL) and separated the organic phase which was dried 
over anhydrous Na2SO4. The solvent was removed by rotary evaporation and the residue was 
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purified by a flash column chromatography on silica gel eluting with AcOEt: Hexane (1:1), to obtain 
product 3 (4.70 g, 21.52 mmol, 72%), as a colorless oil. 
Rf (AcOEt/Hexane 1:1): 0 
1H NMR (500 MHz, CDCl3): δ 3.687–3.619 (m, 10H, OCH2CH2O and CH2CH2N3), 3.515 (t, J = 5 Hz, 
2H, CH2CH2NH2), 3.388 (t, J=5 Hz, 2H, CH2N3), 2.881–2.861 (m, 2H, CH2NH2), 1.806 (s, 2H, NH2). 
13C NMR (125.7 MHz, CDCl3): δ 73.387 (CH2CH2NH2), 70.851, 70.801, 70.772, 70.422, 70.162 (CH2O) 
50.841 (CH2N3), 41.857 (CH2NH2). 
HRMS calcd for C8H18N4O3 [M + H]+: 219.1452; found 219.1447 
N-(2-propin-1-yl) oleamide (4) 
A solution of propargylamine (0.15 mL, 2.34 mmol) and dimethylaminopyridine (0.066 g, 0.54 
mmol) in dry CH2Cl2 (4 mL) was added to a solution of oleoyl chloride (0.50 g, 1.8 mmol) and 
diisopropylcarbodiimide (0.4 mL, 2.7 mmol) in dry CH2Cl2 (4 mL), under argon atmosphere and was 
stirred overnight. Afterwards the reaction was dissolved in CH2Cl2 then was treated with HCl 4N (2 
× 7 mL), neutralized with NaHCO3 (7 mL) and finally washed with brine (7 mL). The organic phase 
was dried over anhydrous Na2SO4, and the solvent evaporated to afford the crude product. To obtain 
the pure product 5 (0.505 g, 1.34 mmol, 57%), as a white solid, the crude was purified with column 
chromatography on silica gel using AcOEt: Hexane (1:5).   
Rf (Hexane/AcOEt 3:1): 0.55 
1H NMR (500 MHz, CDCl3): δ 5.579 (bs, 1H, NHCO), 5.390–5.353 (m, 2H, CH=CH), 4.079 (m, 2H, 
HCCCH2NHCO), 2.249–2.230 (m, 1H, HCCCH2NHCO), 2.225–2.194 (m, 2H, HNCOCH2), 2.051–2.011 
(m, 4H, CH2CH=CHCH2), 1.673–1.644 (m, 2H, HNCOCH2CH2), 1.326–1.292 (m, 20H, CH2), 0.905 (t, 
3H, J = 7 Hz, CH3). 
13C NMR (125.7 MHz, CDCl3): δ 170.37 (COO), 155,67 (CONH), 79.967 (t-BuC), 70,729, 70.683, 70.662, 
70.049, 68.914, 64.361, 60.365, 53.401, 50.712, 42.429 (BocNHCH2COO), 28.313. 
HRMS calcd for C21H37NONa [M + Na] +: 342.2753, found 342.2767. 
[(Z)-4-Octadec-9-enoic-amidomethyl-1H-(1,2,3-Triazol-1-yl)]-3,6,9-trioxaundecan-amine (5) 
A solution of 3 (0.25 g, 0.71 mmol) and 4 (0.23 g, 0.71 mmol), in CH2Cl2 (6 mL), was added to a 
solution of CuSO4 (0.018 g, 0.11 mmol) and sodium ascorbate (0,059 g, 0.30 mmol) in water (8 mL). 
Afterwards, the reaction mixture was stirred vigorously over three days. Then the mixture was 
separated and the organic phase was dried over anhydrous Na2SO4. The CH2Cl2 was removed by 
rotary evaporation to yield the crude product. The triazole derivative, was isolated by flash column 
chromatography on silica gel, eluting with a CH2Cl2:MeOH (9:1) mixture. Thus, product 5 was 
obtained as a white solid (0.34 g, 0.51 mmol, 30%). 
Rf (CH2Cl2/MeOH 9:1): 0.08 
1H NMR (500 MHz, MeOD): δ 7.802 (s, 1H, H-triazol), 5.388–5.232 (m, 2H, CH=CH), 4.473 (t, J = 6, 
2H, CH2CH2triazole), 4.254 (s, 2H, NHCH2-triazol), 3.796 (t, J=5 Hz, 2H, CH2-triazol), 3.606–3.596 (m, 
2H, CH2CH2NH2), 3.550–3.503 (m, 8H, OCH2CH2O), 3.032 (s, 2H, CH2NH2), 2.121 (t, J= 7.5 Hz, 2H, 
CH2CO), 1.934–1.922 (m, 4H, CH2CH=CHCH2), 1.7914–1.733 (m ,2H, NH2), 1.513 (m, 2H, CH2), 1.220–
1.194 (m, 20H, CH2 oleic acid), 0.799 (t, J = 7 Hz, 3H, CH3). 
13C NMR (125.7 MHz, MeOD): δ 176.191 (C=O), 130.871, 130.772 (C=C), 124.903, 71.496, 71.354, 71.342, 
71.224, 70.373, 68.152, 51.376, 36.965, 35.543, 33.026, 30.807, 30.5272, 30.406, 30.330, 30.309, 30.298, 
30.216, 28.123, 28.104, 26.916, 23.702, 14.438.  
HRMS calcd for C29H55N5O4 [M + H] +: 538.43; found 538.43. 
(Z)-(1-azido-3,6,9-trioxaundecan)-oleamide (6) 
To a solution of 3 (0.10 g, 0.46 mmol) in dry CH2Cl2 (0.58 mL), under argon atmosphere, Et3N 
(0.042 mL, 0.56 mmol) and oleoyl chloride (0.066 mL, 0.46 mmol) were added, and the reaction was 
vigorously stirred for 1 day at room temperature. Then, CH2Cl2 (10 mL) was added and extracted 
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with HCl 1N (3 × 5 mL). The organic phase was washed with a saturated aqueous NaHCO3 solution 
(5 mL). The organic phase was dried over anhydrous Na2SO4. The solvent was evaporated and the 
product was purified by flash column chromatography on silica gel with CH2Cl2:MeOH (15:1) to yield 
compound 6 (0.123g, 57 %), as a white solid. 
Rf (CH2Cl2/MeOH 9:1): 0.60  
1H NMR (500 MHz, CDCl3): δ 5.986 (s, 1H, NHCO), 5.353–5.328 (m, 2H, CH=CH), 3.690–3.60 (m, 10H, 
OCH2CH2O and CH2CH2N3), 3.459 (t, J = 5 Hz, 2H, OCH2CH2NHCO), 3.470–3.449 (m, 2H, 
CH2CH2NHCO), 3.390 (t, J = 5, 2H, CH2N3), 2.168 (t, J = 7.5 Hz, 2H, CH2CO), 2.024–1.986 (m, 4H, 
CH2CH=CHCH2), 1.638–1.609 (m, 2H, CH2CH2CO), 1.300–1.253 (m, 20H, CH2 oleic acid), 0.892 (t, J = 
6.5 Hz, 3H, CH3). 
13C NMR (125.7 MHz, CDCl3): 173.380 (C=O), 130.132, 129.905 (C=C), 70.886, 70.787, 70.738, 70.399, 
70.226, 70.121, 50.836, 39.294, 36.889, 32.044, 29.913, 29.878, 29.837, 29.665, 29.457, 29.314, 27.365, 
27.336, 25.886, 22.820, 14.249. 
HRMS calcd for C26H50N4O4Na [M + Na] +: 505.3724; found 505.3718 
1-amino-3,6,9-trioxaundecan-(Z)-9-Octadecenamide (7) 
To a solution of the azide 9 (0.423 g, 0.88 mmol) in dry THF (3.83 mL), under argon atmosphere, 
and cooled to 0 °C, 1.75 mL (1.75 mmol) of a 1M LAH solution in THF was added. After stirring at 0 
°C for 1 h, the reaction mixture was quenched with saturated Na2SO4 aqueous solution (0.62 mL), and 
stirred for 30 min, at room temperature. The white precipitate (aluminium salts) formed, was filtered 
over celite and washed with ether (5 × 10 mL) and then with CH2Cl2 (10 mL). The combined organic 
phases were dried over anhydrous Na2SO4, filtered and concentrate. The residue was purified by 
flash column chromatography on silica gel using CH2Cl2: MeOH (15:1) as eluent, to yield the product 
7 (0.261 g, 0.57 mmol, 65%), as a colorless oil. 
Rf (CH2Cl2/MeOH 15:1) = 0 
1H NMR (500 MHz, CDCl3): δ 6.632 (s, 1H, NHCO), 5.350–5.325 (m, 2H, CH=CH), 3.657–3.557 (m, 
10H, OCH2CH2O and OCH2CH2NH2), 3.482–3.436 (m, 2H, CH2CH2NHCO), 3.036–3.031 (m, 2H, 
CH2NHCO), 2.985–2.957 (m, 2H, CH2NH2), 2.937–2.924 (m, 2H, NH2), 2.204–2.174 (m, 2H, CH2CO), 
2.022–1.984 (m, 4H, CH2CH=CHCH2), 1.634–1.605 (m, 2H, CH2CH2CONH), 1.298–1.266 (m, 20H, CH2 
oleic acid), 0.878 (t, J = 7 Hz, 3H, CH3). 
13C NMR (125.7 MHz, CDCl3): δ 173.682 (C=O), 130.118, 129.906 (C=C), 70.603, 70.560, 70.303, 70.248, 
39.308, 36.808, 32.036, 29.908, 29.888, 29.834, 29.791, 29.657, 29.484, 29.467, 29.444, 29.333, 27.363, 
27.340, 25.930, 22.811, 14.237  
HRMS calcd for C26H52N2O4 [M + H] + : 457.71; found 457.40 
3. Results and Discussion Section 
3.1. Synthesis of the Amphiphilic Compounds 
The first synthesized amphiphilic compound, 5, has a tetraethylene glycol chain as a spacer, the 
versatile amine group as a polar head and the oleic acid fragment as a lipophilic tail. It was obtained 
through a five steps sequence (Scheme 3). 
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Scheme 3. Synthesis of the amphiphilic compound 5. 
Mesylation of tetraethylene glycol with mesyl chloride gave the dimesylated derivative 1, which 
was transformed into diazide 2 by substitution with sodium azide, and then reduced with 
triphenylphosphine to yield compound 3. The linking of 3 to the lipidic part of the amphiphilic 
compound was carried out through a Cu (I) catalyzed Huisgen reaction. Whith this purpous, the 
corresponding alkynyl derivative of oleic acid 4 was previously prepared by amidation of oleic acid 
with propargylamine, and the Huisgen reaction was carried out with the corresponding azide 3, 
obtaining the final compound 5. The presence of the amine group in 5, as a versatil polar head, may 
constitute a binding site to other specific functional groups as a drug, a recognition ligand or an 
anionic group like phosphonate.  
In the case of the second synthesized amphiphilic compound 7, with a structure similar to that 
of compound 5, the connection between the polar head and the lipophilic chain is an amide group 
instead of a triazole one (Scheme 4). 
 
Scheme 4. Synthesis of the amphiphilic compound 7. 
The reaction between compound 3 and oleoyl chloride yielded the amide 6, and the subsequent 
regioselective reduction of the azide group with LAH gave compound 7, without reducing the amide 
function. 
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3.2. Preparation and Characterization Of Micelles  
In all cases, the range of CMC obtained was [0.01 mM–0.08 mM] using the pyrene method 24], 
very similar to the CMC values of polymeric micelles 25–27]. 
Micelles were formed in water solutions at a concentration of 1.25 mg/mL (0.02 M in the case of 
compound 7) much greater than CMC. Micelle formation process was previously optimized and 
consists on the dispersion of the amphiphilic compound in MilliQ water. Then, the sample was 
ultrasonicated by a sonic tip (Digital ultrasonic sonicator Q500 of 500 watts), for 30 min. After 
sonication, a microfiltration process was carried out with a 30 mm membrane filter (Interlab Ltd. 
Customables syringe filters) in order to eliminate suspended particles.  
Micelles were then characterised by DLS and TEM. Figure 2 represents two electronic 
transmission microscope pictures with different magnification of micelles obtained from amphiphilic 
compound 5 (M5). As it can be seen, micelles are monodisperse, therefore aggregates are not present, 
and they have sizes in a range of 50–89 nm. 
 
Figure 2. TEM images of M5. 
In addition to microscopic analysis, the sample was analysed by DLS (Dynamic light scattering) 
in order to determine their hydrodynamic size. In the case of M5, it was of 99.80 nm (Figure 3). 
 
Figure 3. DLS Analysis of M5. 
As can be seen, both techniques determined similar micelles size. 
Figure 4 represents a TEM photograph of micelles from compound 7 (M7) with diameters 
between 70–120 nm and DLS results with hydrodynamic size of 40 nm.  
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Figure 4. TEM and DLS Analysis of M7. 
In this case, one more time, both techniques confirm the presence of micelles. 
3.3. Inclusion of Dexamethasone in Micelles  
Dexamethasone (Dexa) was introduced in the synthesized micelles, in order to verify the ability 
of these nanocarriers to contain a highly insoluble drug. This test was performed using synthesized 
micelles of compound 5 (M5) and 7 (M7) (Table 1).  
A procedure in 3 steps has been carried out: 
(i) Addition of the solid drug (5.9 mg) directly to the previously prepared water solution of micelles 
and stirring 72 h at 50 °C. During this time, the sample was covered with an aluminum foil to 
prevent the degradation of the photosensitive drug Dexamethasone. 
(ii) Centrifugation at 2000 rpm during 15 min, obtaining a precipitate, which represents the drug 
not included, and a solution containing the micelles with the drug inside. 
(iii) Lyophilization for the elimination of water from the samples. 
Table 1. Drug and micelles quantities (in mg) before and after the inclusion process. 
Initial mg of 
Dexa 
Initial mg of 
Amphiphile 
mg of Dexa 
as a 
Precipitate 
Mg of Micelle + 
Dexa 
mg of Dexa 
Included in 
Micelles 




10 mg of 5 
(in 8 mL H2O milliQ) 
2.7 mg 13.2 mg 3.2 mg 54.2% 
6.2 mg 
10 mg of 7 
(in 10 mL H2O miliQ) 
1.6 mg 14.6 mg 4.6 mg 74.2% 
To confirm the inclusion of the drug in the micelle, the analysis of the samples by 1H-NMR using 
different deuterated solvents has been carried out and the results obtained are shown in Figure 5. 
 
(a) 
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Figure 5. (a) 1H-NMR of dexamethasone in deuterated DMSO. (b) 1H-NMR of 5 in D2O. (c) 1H-NMR 
of (M5) in D2O. (d) 1H-NMR of M5 + dexamethasone in D2O. (e) 1H-NMR of M5 + Dexamethasone in 
deuterated DMSO. (f) 1H-NMR of 7 in D2O. (g) 1H-NMR of (M7) in D2O. (h) 1H-NMR of M7 + 
dexamethasone in D2O. (i) 1H-NMR of M7 + Dexamethasone deuterated DMSO. 
1H-RMN of micelles + Dexa in D2O highlights only the signals corresponding to the protons of 
the amphiphilic compound, whereas 1H-NMR of micelles + Dexa in DMSO which is an organic 
solvent and causes the leakage of the drug, shows the proton signals corresponding to both, the 
amphiphilic compound and Dexamethasone. This analysis represents a further indication of the 
internalization of the drug (Scheme 5). 
In conclusion, it is possible to considerate that the drug is located inside the hydrophobic cavity 
of the micelles. This is evidenced not only by a gravimetric method, but also by NMR which shows 
all the signals corresponding to the drug.  
8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 ppm
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Scheme 5. Representation of micelles + Dexa in D2O (a) and amphiphilic compounds + Dexa in 
DMSO-d (b). 
4. Conclusions 
The goals of this experimental work were to synthesize a new family of amphiphilic compounds 
in order to obtain micelles as drug nanocarriers. For this purpose, we prepared two amphiphilic 
compounds 5 and 7, with an amine as a versatile polar head, which lead to the corresponding 
micelles, M5 and M7 respectively, characterized by DLS and TEM, which have different sizes and 
distribution in water. 
In order to verify the ability of these micelles, characterized by an average size of about 100 nm, 
as drug transport agents, the inclusion of the highly lipophilic drug Dexamethasone into both 
micelles M5 and M7 was performed, containing about 54 % and 74% of the previously added drug, 
respectively. This represents a good percentage and demonstrates their ability to encapsulate a highly 
lipophilic drug in their core. 
As a project in the near future, in vitro release of encapsulated Dexa studies will be performed 
and M5 and M7 micelles will be functionalized by exploiting the free amine groups of their 
amphiphilic monomers, in order to address them to a specific target.  
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